Derivation of eggs or sperm from pluripotent stem cells or direct reprogramming from somatic cells would have huge effects on assisted reproductive technology. Here we discuss important ethical, legal, and social issues that would be raised by the development of such female or male gametes for clinical use.
consensus paper onvarious issues concerning stem cell-derived gametes (Hinxton Group, 2008 ). The time is right to reconsider the research response to the production of human germ cells in vitro from PSCs or somatic cells, as well as what steps might ensure the ability to move research to clinical applications. This research should improve our understanding of human developmental biology and should contribute to advancing knowledge of the pathology, diagnosis, and uses of assisted reproductive technology (ART). As we move forward, however, many ethical, legal, and social issues lie ahead.
One key issue is the need to assess the function of induced germ cells; this implies the need for research that tests human induced sperm and eggs to determine if they can successfully participate in fertilization and can produce normal embryos. For example, generation of sperm and eggs positive for specific male and female germ cell markers and negative for those specific to pluripotent stem cells should be ensured.
Additionally, appropriate epigenetic programming, properly imprinted sperm and egg chromatin, and appropriate organization of the sperm and egg nucleus and mitochondrial structure should be evaluated. Thereafter, the creation of human embryos may, as a final biological assay, be exceptionally necessary in a preclinical stage to ensure safety of the induced cells. Currently, many countries allow derivation of hESCs from surplus in vitro fertilization (IVF) embryos, subject to some conditions, but many jurisdictions limit or ban production of human embryos for research purposes.
This raises the question of where and under what circumstances the research necessary to explore the medical potential of human induced germ cells can be legally and ethically performed. Should such cells be brought to the clinic, a different set of controversial issues will appear. In this article, we scrutinize the questions concerning embryo research and point out some of the issues that eventual clinical use will raise.
Creating Human Embryos for Research
In fertility clinics, ART generally begins with ovulation via hormonal stimulation followed by oocyte retrieval for IVF. In cases of male infertility, the use of intracytoplasmic sperm injection (ICSI) is often required to produce viable embryos with one or a few sperm. Following fertilization, embryos are cultured, generally for 3 -5 days and one or more is selected for transfer to the uterus (Niakan et al., 2012) .
Remaining pre-implantation embryos are then either stored under cryopreservation for future embryo transfer to a patient or discarded. Following successful pregnancies, cryopreserved embryos may subsequently be discarded, given to other prospective parents, or donated to research. Research that makes use of surplus embryos must meet guidelines of institutional review boards (IRB) or equivalent bodies, especially in terms of prior informed consent of parental donors. Notably, the derivation of hESC lines is generally conducted using the existing and surplus embryos that were originally created for ART and are no longer required for reproductive purposes. For many people, and governments, the fact that the embryos were initially created for reproductive purposes is crucial to their ethical use for research once intended reproductive uses are no longer contemplated.
International Regulatory Landscape
Regarding national policy of human embryo creation for research purposes, we investigated 17 countries that permit hESC derivation from the surplus embryos (Supplemental Table 1 ). Fifteen of these countries permit creation of embryos for research purposes in at least some circumstances: Australia, Belgium, Canada, China, Denmark, India, Israel, Japan, Singapore, South Africa, South Korea, Spain, Sweden, UK, and US (in some but not all states). All of these countries, by statutes or by guidelines, limit the culture period of the created embryo to either the 14th day of embryo development or the formation of primitive streak, which begins roughly at that time. This restriction has been justified on the ground that the formation of the primitive streak signifies the start of a unique, human being (President's Council on Bioethics, 2002) . In some of the permissive countries, researchers are required to provide specific justification for why they need to create embryos for research. In Australia, Belgium, Canada, India, Israel, Japan, Singapore, South Africa, South Korea, Spain and the UK, the laws or guidelines require a public license or authorization to create human embryos for research. In addition to the need to account for the creation of embryos for research purposes, some explanation for the decision not to use surplus IVF embryos is also required in review process.
In countries that allow creation of embryos for research, therapeutic cloning using somatic cell nuclear transfer is frequently indicated as a permitted purpose.
Others include hESC derivation, parthenogenesis, and special embryos including "hybrid embryos" in Australia and "cytoplasmic hybrids" in Singapore and UK.
Belgium, Canada, Denmark, Japan and UK permit research that creates human embryos for improving or providing instruction in ART. The Australian act indicated the possibility of creating human embryos using "precursor cells" from human embryos.
Notably, the "precursor cells" might be regarded as the germ cells induced from hESCs but not from hiPSCs. Japan has guidelines for inducing germ cells from human iPSCs, ESCs and tissue-specific stem cells, but those guidelines currently prohibit fertilization using the induced germ cells. Thus, it seems clear that researchers in Australia, Belgium, Canada, Denmark and the UK, might, after prior consultation or permission from a regulatory authority, be allowed to create human embryos and develop them in culture for about 14 days in order to investigate developmental potential of the induced germ cells.
In the US, current federal laws and NIH guidelines only prohibit federal funding of research that results in destruction or risk of damage to human embryos.
Research that does not receive federal funding is not subject to that restriction. In contrast, several states enacted statutes that directly impact human embryo research. The main difference that we see of possible ethical significance is that embryos created from induced germ cells from hiPSCs would not require the process of gamete donation, which, for women, is unpleasant and risky. This difference, however, seems to be minor compared to the overall similarities given that all embryos have the potential to become human life. As a result, all the embryos created either for research 
